Clinical Trial Update: MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MRG003 induction followed by capecitabine maintenance with a PD-1 inhibitor in locally recurrent nasopharyngeal carcinoma; rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• MRG003

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Nasopharyngeal Carcinoma, Local Recurrence | Phase 2 | Status: NOT_YET_RECRUITING